{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.13","value":"2.3"},{"groupId":"OG001","spread":"18.86","value":"5.6"},{"groupId":"OG002","spread":"19.41","value":"6.1"}]}],"title":"Cycle 4 - approximately Month 4 (n=114,121,125)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.95","value":"8.0"},{"groupId":"OG001","spread":"22.48","value":"8.1"},{"groupId":"OG002","spread":"23.92","value":"4.2"}]}],"title":"Cycle 7 - approximately Month 7 (n=96,108,110)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.33","value":"12.4"},{"groupId":"OG001","spread":"24.70","value":"8.8"},{"groupId":"OG002","spread":"24.60","value":"6.2"}]}],"title":"Cycle 10 - approximately Month 10 (n=84,86,96)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.32","value":"7.6"},{"groupId":"OG001","spread":"24.02","value":"8.8"},{"groupId":"OG002","spread":"22.80","value":"5.4"}]}],"title":"Cycle 13 - approximately Month 13 (n=70,70,82)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.28","value":"10.7"},{"groupId":"OG001","spread":"26.29","value":"7.2"},{"groupId":"OG002","spread":"25.11","value":"8.1"}]}],"title":"Cycle 16 - approximately Month 16 (n=61,50,62)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}